SignalXSignalX

TXG 10x Genomics, Inc.

Q3 2025 10-Q
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Laboratory Analytical InstrumentsSEC EDGAR
10x Genomics, Inc. Overview

10x Genomics, Inc. (TXG) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New acquisition risk from Scale Biosciences asset acquisition in August 2025 with $20M technology transfer payment due Q1 2026 and up to $30M contingent consideration
  • • Material update on patent litigation settlements with Vizgen and Bruker, generating total $94M upfront with gain on settlements boosting first-half 2025 revenues
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$149M

Net Income

-$27M

Gross Margin

67.3%

Operating Margin

-21.6%

Net Margin

-18.4%

ROE

-3.5%

Total Assets

$1.0B

Source: XBRL data from 10x Genomics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on 10x Genomics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.